IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
116 hedge funds and large institutions have $1.36B invested in IVERIC bio, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 9 closing their positions.
278% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 9
83% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 23
26% more funds holding
Funds holding: 92 → 116 (+24)
20% more capital invested
Capital invested by funds: $1.13B → $1.36B (+$228M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
40% less call options, than puts
Call options by funds: $2.92M | Put options by funds: $4.84M
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$22M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$18.7M |
| 3 |
Morgan Stanley
New York
|
+$15.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 5 |
JCG
JHL Capital Group
Chicago,
Illinois
|
+$8.19M |
Top Sellers
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$41.8M |
| 2 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$28.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.7M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.7M |
| 5 |
PA
Perceptive Advisors
New York
|
-$3.81M |
ISEE Hedge Fund Activity: Q4 2014 in Review
116 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q4 2014, worth a combined $1.36B — up 20% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ISEE positions and 9 closed out — a net gain of 25 holders — while 42 added to existing stakes and 23 trimmed.
The largest buyer was OrbiMed, adding an estimated $22M. The largest seller was Novo Holdings A/S, cutting an estimated $41.8M.
- 116 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q4 2014, up from 92 in Q3 2014.
- Funds reported $1.36B of IVERIC bio, Inc. Common Stock stock for Q4 2014, up 20% quarter-over-quarter.
- 34 funds opened new IVERIC bio, Inc. Common Stock positions in Q4 2014 and 9 closed out, a net change of +25 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q4 2014 was OrbiMed, an estimated $22M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q4 2014 was Novo Holdings A/S, an estimated $41.8M sold.
Based on aggregated 13F filings for Q4 2014.